Endoscopy 2023; 55(12): 1151
DOI: 10.1055/a-2131-3315
Letter to the editor

Colonoscopy setting and impact on statistical significance in Artificial Intelligence trials

Marco Spadaccini
1   Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
2   Endoscopy Unit, Humanitas Clinical and Research Center – IRCCS, Rozzano, Italy
,
3   Gastroenterology Department, Valduce Hospital, Como, Italy
,
3   Gastroenterology Department, Valduce Hospital, Como, Italy
,
4   Clinical Effectiveness Research Group, University of Oslo, Oslo, Norway
5   Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan
,
Cesare Hassan
1   Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
2   Endoscopy Unit, Humanitas Clinical and Research Center – IRCCS, Rozzano, Italy
,
Alessandro Repici
1   Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
2   Endoscopy Unit, Humanitas Clinical and Research Center – IRCCS, Rozzano, Italy
› Author Affiliations

We read with interest the article by Ahmad et al. [1] investigating the impact of artificial intelligence (AI) on adenoma detection in a fecal immunochemical test (FIT)-based screening colonoscopy setting.

In our opinion the colonoscopy setting of the study is the main reason for the lack of statistically significant difference found in the adenoma detection rate (ADR). The FIT-based colonoscopy setting has always been considered a challenging area in which to test technologies aimed at improving the ADR. This is due to the higher prevalence of adenomas expected in this setting [2], reducing the relative statistical weight of any absolute difference that may be found. We previously investigated the impact of using AI in a FIT-based colonoscopy screening program in Italy, obtaining a statistically significant absolute increase of 8 % in ADR in the AI group (53.6 % vs. 45.3 %) [3]. This result appears to be similar to the 6 % absolute difference described in the Ahmad et al. study.

The higher cutoff for FIT positivity in the UK (80–150 µg Hb/g) [4] compared with Italy (20 µg Hb/g) selects a cohort of patients with a higher prevalence of adenomas; furthermore, the extensive use of the mucosal exposure device in the study minimized the risk of missing lesions [5]. Both these factors increase the expected baseline ADR in this study, marginalizing the relative (statistical) impact of AI. This might have been avoided by calculating the sample size based on an appropriate baseline ADR, with consequently a huge number of colonoscopies needed to prove any difference. By calculating the sample size based on the polyp detection rate, as Ahmad et al. did, the impact of AI on adenoma detection performance was probably underestimated.



Publication History

Article published online:
28 November 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany